---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-003026"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:58:09.179461+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara reports positive TARA-002 NMIBC data; expects key milestones in 2025; cash runway into 2027

## Summary
- TARA-002 in NMIBC: 72% CR at six months, 70% at any time; 100% maintained CR from 3 to 6 months; no Grade 2+ TRAEs.
- Expects 12-month evaluable data mid-2025 and futility analysis of ~25 BCG-unresponsive patients by end 2025.
- Expects to start THRIVE-3 registrational trial of IV Choline Chloride in 1H 2025; FDA Fast Track granted.
- TARA-002 in LMs: initial results from additional STARBORN-1 cohorts expected by end of 1H 2025.
- Cash of $81.5M plus ~$100M gross from December offering (including partial option exercise) funds operations into 2027.

## SEC filing metadata
- accession: 0001213900-25-003026
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/0001213900-25-003026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea0227457-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-003026
- JSON: https://secwatch.observer/filing/0001213900-25-003026.json
- Plain text: https://secwatch.observer/filing/0001213900-25-003026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.